Mitochondrial-Targeted Peptides
Elamipretide
Also known as SS-31 · Forzinity
Last reviewed: 2026-11-19
Overview
A mitochondrial-targeted tetrapeptide also known as SS-31.
Regulatory status
FDA approval applies only to the named products and indications below. It does not approve every formulation or other use.
Forzinity · Barth Syndrome
Improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kilograms; accelerated approval, with confirmatory evidence required.
Authoritative label record
Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.
WADA prohibited status: current list and contextEvidence at a glance
Forzinity has accelerated approval for improving muscle strength in people with Barth syndrome weighing at least 30 kg; this does not establish benefit for aging or other mitochondrial conditions.
Key sources
Targeted factual corrections checked against the sources below on November 19, 2026. This is not an exhaustive systematic review; discovery dates, exact molecular forms and current labels require separate verification.
Related compounds
- MOTS-c
Same scientific class · A 16-amino-acid chain. · Animal studies